EP1883419A4 - Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use - Google Patents
Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of useInfo
- Publication number
- EP1883419A4 EP1883419A4 EP06759154A EP06759154A EP1883419A4 EP 1883419 A4 EP1883419 A4 EP 1883419A4 EP 06759154 A EP06759154 A EP 06759154A EP 06759154 A EP06759154 A EP 06759154A EP 1883419 A4 EP1883419 A4 EP 1883419A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- glp
- glucagon
- peptide
- receptor agonists
- pharmacological methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67872305P | 2005-05-06 | 2005-05-06 | |
PCT/US2006/017411 WO2006121860A2 (en) | 2005-05-06 | 2006-05-05 | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1883419A2 EP1883419A2 (en) | 2008-02-06 |
EP1883419A4 true EP1883419A4 (en) | 2010-08-04 |
Family
ID=37397130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06759154A Withdrawn EP1883419A4 (en) | 2005-05-06 | 2006-05-05 | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1883419A4 (en) |
JP (1) | JP2008539735A (en) |
CA (1) | CA2607566A1 (en) |
WO (1) | WO2006121860A2 (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2009108280A (en) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
US20100256056A1 (en) * | 2007-09-07 | 2010-10-07 | Zheng Xin Dong | Analogues of exendin-4 and exendin-3 |
DE102007054497B3 (en) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | New crystalline hydrate form of dodecanedioic acid 4-((2S,3R)-3-((S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl)-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl)-benzylamide ((2S,3R,4R,5R)-pentahydroxy-hexyl)-amide useful e.g. to treat hyperlipidemia |
KR101277560B1 (en) * | 2007-12-11 | 2013-06-25 | 카딜라 핼쓰캐어 리미티드 | Peptidomimetics with glucagon antagonistic and GLP-1 agonistic activities |
WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
WO2011023754A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi-Aventis | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
TW201124391A (en) | 2009-10-20 | 2011-07-16 | Lundbeck & Co As H | 2-substituted-ethynylthiazole derivatives and uses of same |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
AR080592A1 (en) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | PEPTIDE WITH ACTIVITY FOR GIP-R AND GLP-1-R, FAMILY FORMULATION THAT UNDERSTANDS IT, ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF MELLITUS DIABETES AND TO INDICATE WEIGHT LOSS |
DE102010015123A1 (en) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels |
EP2582709B1 (en) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
EP2683699B1 (en) | 2011-03-08 | 2015-06-24 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683704B1 (en) | 2011-03-08 | 2014-12-17 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US20120282255A1 (en) * | 2011-04-07 | 2012-11-08 | Greg Plucinski | Methods and compositions for the treatment of alcoholism and alcohol dependence |
CN108892709A (en) | 2011-05-18 | 2018-11-27 | 欧莫德里斯制药公司 | The peptide medicine of improvement |
KR102011924B1 (en) * | 2011-05-18 | 2019-08-21 | 메더리스 다이어비티즈, 엘엘씨 | Improved peptide pharmaceuticals for insulin resistance |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
AR090937A1 (en) * | 2012-05-03 | 2014-12-17 | Zealand Pharma As | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS FOR USE |
FR2991055B1 (en) * | 2012-05-22 | 2014-06-13 | C2 Diagnostics | FLUIDIC CONNECTION DEVICE FOR BIOLOGICAL ANALYSIS APPARATUS, FLUIDIC COMPONENT ADAPTED AND BIOLOGICAL ANALYSIS APPARATUS THUS EQUIPPED THEREFOR; |
CN109456400A (en) | 2012-07-23 | 2019-03-12 | 西兰制药公司 | Glucagon analogue |
TWI608013B (en) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | Glucagon analogues |
EP2906243A4 (en) * | 2012-10-11 | 2016-08-17 | Univ Tufts | Compositions and methods for sustained delivery of glucagon-like peptide (glp-1) receptor agonist therapeutics |
MX360816B (en) | 2012-11-20 | 2018-11-15 | Mederis Diabetes Llc | Improved peptide pharmaceuticals for insulin resistance. |
EP3444281B1 (en) | 2012-11-20 | 2021-11-03 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
PT3057984T (en) | 2013-10-17 | 2018-10-24 | Boehringer Ingelheim Int | Acylated glucagon analogues |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
CN105849122B (en) | 2013-11-06 | 2021-04-30 | 西兰制药公司 | GIP-GLP-1 dual agonist compounds and methods |
CA2929107C (en) | 2013-11-06 | 2023-09-26 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
MX371033B (en) * | 2014-05-28 | 2020-01-13 | Mederis Diabetes Llc | Improved peptide pharmaceuticals for insulin resistance. |
EP3985016A1 (en) | 2014-10-29 | 2022-04-20 | Zealand Pharma A/S | Gip agonist compounds and methods |
US10336802B2 (en) | 2015-04-16 | 2019-07-02 | Zealand Pharma A/S | Acylated glucagon analogue |
EP3735295A1 (en) | 2018-01-03 | 2020-11-11 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for treatment of nash and other disorders |
MX2020009950A (en) * | 2018-03-23 | 2021-04-28 | Carmot Therapeutics Inc | Modulators of g-protein coupled receptors. |
PL3774862T3 (en) | 2018-04-05 | 2022-10-03 | Sun Pharmaceutical Industries Limited | Novel glp-1 analogues |
CN108676084B (en) * | 2018-05-31 | 2021-12-03 | 长春百克生物科技股份公司 | Exenatide modifier and application thereof |
CN109021093B (en) * | 2018-08-29 | 2021-09-07 | 上海生物制品研究所有限责任公司 | Polyethylene glycol modified GLP-1 derivatives and medicinal salts thereof |
CN111410687B (en) * | 2020-02-21 | 2023-06-27 | 成都奥达生物科技有限公司 | Long-acting GLP-1 compound |
CN113461785B (en) * | 2021-04-13 | 2022-10-14 | 湖南中晟全肽生化有限公司 | GLP-1 receptor agonists and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043707A1 (en) * | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
WO2000066629A1 (en) * | 1999-04-30 | 2000-11-09 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
WO2004022004A2 (en) * | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
WO2004093823A2 (en) * | 2003-03-19 | 2004-11-04 | Eli Lilly And Company | Polyethelene glycol link glp-1 compounds |
US6864069B2 (en) * | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
US7067488B2 (en) * | 2002-09-25 | 2006-06-27 | Theratechnologies Inc. | Modified GLP-1 peptides with increased biological potency |
-
2006
- 2006-05-05 WO PCT/US2006/017411 patent/WO2006121860A2/en active Application Filing
- 2006-05-05 CA CA002607566A patent/CA2607566A1/en not_active Abandoned
- 2006-05-05 EP EP06759154A patent/EP1883419A4/en not_active Withdrawn
- 2006-05-05 JP JP2008510259A patent/JP2008539735A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999043707A1 (en) * | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
WO2000066629A1 (en) * | 1999-04-30 | 2000-11-09 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6864069B2 (en) * | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
WO2004022004A2 (en) * | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
WO2004093823A2 (en) * | 2003-03-19 | 2004-11-04 | Eli Lilly And Company | Polyethelene glycol link glp-1 compounds |
Non-Patent Citations (2)
Title |
---|
ROBERTS M J ET AL: "Chemistry for peptide and protein PEGylation", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL LNKD- DOI:10.1016/S0169-409X(02)00022-4, vol. 54, no. 4, 17 June 2002 (2002-06-17), pages 459 - 476, XP002293146, ISSN: 0169-409X * |
VERONESE F M: "Peptide and protein PEGylation - a review of problems and solutions", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB LNKD- DOI:10.1016/S0142-9612(00)00193-9, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612 * |
Also Published As
Publication number | Publication date |
---|---|
CA2607566A1 (en) | 2006-11-16 |
EP1883419A2 (en) | 2008-02-06 |
JP2008539735A (en) | 2008-11-20 |
WO2006121860A2 (en) | 2006-11-16 |
WO2006121860A3 (en) | 2007-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1883419A4 (en) | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use | |
AU2003273300A8 (en) | Modified glp-1 receptor agonists and their pharmacological methods of use | |
HK1073117A1 (en) | Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use | |
IL176223A0 (en) | The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same | |
IL177066A0 (en) | Combined use of a glp-1 agonist and gastrin compounds | |
AU2003239478A8 (en) | Modified glucagon-like peptide-1 analogs | |
WO2006097536A3 (en) | Dimeric peptide agonists of the glp-1 receptor | |
IL189670A0 (en) | Trail receptor 2 polypeptides and antibodies | |
EP1585959A4 (en) | Extended glucagon-like peptide-1 analogs | |
IL184205A0 (en) | Antibodies against il-13 receptor alpha 1 and uses thereof | |
ZA200705674B (en) | Peptides with neuropeptide-2 receptor (Y2R) agonist activity | |
AU5716901A (en) | G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same | |
EP1583503A4 (en) | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof | |
IL178254A0 (en) | Receptor coupling agents and therapeutic uses thereof | |
DK2662390T3 (en) | INTERFERON ALPHA RECEPTOR 1 ANTIBODIES AND USE THEREOF | |
EP1901763A4 (en) | Thyrotropin-releasing hormone analogs and method of use | |
ZA200710699B (en) | Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor | |
EP1942947A4 (en) | Fibronectin polypeptides and methods of use | |
HK1100280A1 (en) | Peptidic vasopressin receptor agonists | |
ZA200802575B (en) | Trail receptor 2 polypeptides and antibodies | |
IL176705A0 (en) | Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | |
EP1896048A4 (en) | Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | |
AU2003273994A8 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43) | |
AU2003276106A8 (en) | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) | |
SI1833847T1 (en) | Igf-1 fusion polypeptides and therapeutic uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20071206 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100701 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110202 |